Last reviewed · How we verify
Retaine™
Retaine is an ophthalmic emulsion that lubricates and protects the ocular surface by supplementing natural tears and reducing evaporation.
Retaine is an ophthalmic emulsion that lubricates and protects the ocular surface by supplementing natural tears and reducing evaporation. Used for Dry eye disease / keratoconjunctivitis sicca.
At a glance
| Generic name | Retaine™ |
|---|---|
| Sponsor | Ocusoft, Inc. |
| Drug class | Artificial tear / ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Retaine contains a lipid-based emulsion (castor oil and other oils) that mimics the lipid layer of the tear film, helping to stabilize tears and reduce evaporative dry eye. By restoring tear film composition and reducing water loss from the ocular surface, it provides symptomatic relief and protects corneal and conjunctival tissues in dry eye disease.
Approved indications
- Dry eye disease / keratoconjunctivitis sicca
Common side effects
- Blurred vision
- Eye irritation
- Mild ocular discomfort
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Retaine™ CI brief — competitive landscape report
- Retaine™ updates RSS · CI watch RSS
- Ocusoft, Inc. portfolio CI